Home » Publications » Clinical trial updates » Improving safety of blood transfusion

Improving safety of blood transfusion




Update: 31 March 2020

Pathogen inactivation of platelet concentrates (PC) with the INTERCEPT Blood System has been universally implemented in metropolitan France from November 2017 onwards.

 The first annual haemovigilance activity report has shown that transfusion monitoring data in 2018 after transfusing ~320.000 PCs are fully in line with expectations, especially with regard to the reduction of transfusion transmitted infectious diseases.

 Notably, no bacterial infection transmitted by transfusion (15 transmissions occurred in previous 5 years) and there was no transmission of arbovirus, HTLV or parasites by transfusion.




Update: 31 January 2020

No update available


Update: 25 November 2019

No update available


Update: 27 September 2019

No update available


Update: 30 July 2019

No update available.


Update: 30 May 2019

No update available.


Update: 01 February 2019

The SPARC study was a randomized, double blinded cross-over study evaluating the efficacy and safety of INTERCEPT RBC in chronic anaemia patients.

A total of 86 thalassemia patients were enrolled at three participating international sites.

The trial was successful in demonstrating safety and efficacy, i.e. that INTERCEPT treated RBCs enable the carrying of more haemoglobin, hence more oxygen around the body and meaning the less need for transfusions and reduction of subsequent iron overload.

Cerus Corporation has filed to obtain CE mark for INTERCEPT RBC system.




Update: 20 December 2018

No update available.


Update: 02 October 2018

Results of a European Phase 3 transfusion study of chronic anaemia evaluating INTERCEPT-treated red blood cells (RBCs) in thalassaemia patients, SPARC (A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassaemia Major Requiring Chronic RBC Transfusion) have been announced at the Annual Congress of the European Hematology Association (EHA), held between 14 – 17 June 2018 in Stockholm, Sweden.

Main results:

  • Study successfully met primary efficacy and safety endpoints (15% relative difference in the mean consumption of haemoglobin between INTERCEPT-treated RBC and conventional RBC)
  • No antibodies detected specific to INTERCEPT treated red blood cells
  • No treatment-emergent antibodies to red blood cell alloantigens